Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent~* Male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) \> 1 year~* C-peptide value of \< 0.7 ng/mL~* Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total daily insulin \>= 0.3 and \<= 1.5 U/kg~* Glycated haemoglobin (HbA1c) \>= 7.5% and \<= 10.0%~* Good understanding of T1DM~* Age \>= 18 years~* Body Mass Index (BMI) \>= 18.5 kg/m2~* Estimated glomerular filtration rate \>= 30 mL/min/1.73 m2~* Women of child-bearing potential must use highly effective methods of birth control~* Compliance with trial medication administration between 80% and 120% during placebo run-in period Further inclusion criteria apply~Exclusion criteria:~* History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis~* Pancreas, pancreatic islet cells or renal transplant recipient~* T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and bolus insulin within last 3 months~* Occurrence of severe hypoglycaemia within last 3 months and until randomisation~* Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6~* Irregular sleep/wake cycle~* Acute coronary syndrome, stroke or Transient Ischaemic Attack (TIA) within last 3 months~* Severe gastroparesis~* Brittle diabetes~* Liver disease~* Eating disorders~* Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen~* Treatment with systemic corticosteroids~* Change in dose of thyroid hormones within last 6 weeks and until randomisation~* Cancer or treatment for cancer in the last five years~* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells~* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial~* Alcohol or drug abuse~* Intake of an investigational drug in another trial within last 30 days Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose (Type: EXPERIMENTAL): None
- Empagliflozin high dose (Type: EXPERIMENTAL): None
- Empagliflozin medium dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).